Acalabrutinib: BTK Inhibitor for CLL and Lymphoma
Acalabrutinib is a targeted cancer drug belonging to the class of BTK inhibitors, used to treat certain B-cell lymphomas and chronic lymphocytic leukemia.
Things worth knowing about "Acalabrutinib"
Acalabrutinib is a targeted cancer drug belonging to the class of BTK inhibitors, used to treat certain B-cell lymphomas and chronic lymphocytic leukemia.
What is Acalabrutinib?
Acalabrutinib is a selective second-generation Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of certain blood cancers. It is a targeted therapy that specifically interferes with signaling pathways in malignant B-lymphocytes, thereby inhibiting their growth and survival. The drug is marketed under the brand name Calquence and is approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Indications
Acalabrutinib is approved for the following conditions:
- Chronic lymphocytic leukemia (CLL): as a first-line treatment as well as after prior therapies
- Mantle cell lymphoma (MCL): in patients who have received at least one prior therapy
Mechanism of Action
Acalabrutinib irreversibly and highly selectively binds to Bruton tyrosine kinase (BTK), an enzyme that plays a central role in the B-cell receptor signaling pathway. By inhibiting BTK, the proliferation, survival, and migration of malignant B-cells are blocked. Compared to its predecessor ibrutinib, acalabrutinib demonstrates greater selectivity for BTK, which is intended to result in an improved side effect profile.
Dosage and Administration
Acalabrutinib is typically administered as a 100 mg oral capsule taken twice daily. It can be taken with or without food. The capsules should not be opened or dissolved. In patients taking proton pump inhibitors (PPIs), absorption may be reduced, so spacing from other medications should be considered and discussed with a physician.
Side Effects
Like all targeted cancer therapies, acalabrutinib can cause side effects. Common side effects include:
- Headache (particularly during the first weeks of treatment)
- Bleeding (e.g., bruising, nosebleeds)
- Diarrhea and nausea
- Infections (e.g., upper respiratory tract infections)
- Muscle and joint pain
- Cardiac arrhythmias (atrial fibrillation)
- Changes in blood counts (e.g., neutropenia, thrombocytopenia)
Rare but serious adverse events include major bleeding episodes and opportunistic infections. Patients should immediately inform their treating physician if unusual symptoms occur.
Drug Interactions
Acalabrutinib is primarily metabolized by the liver enzyme CYP3A4. Therefore, drugs that inhibit or induce this enzyme can affect acalabrutinib blood levels. Strong CYP3A4 inhibitors (e.g., certain antifungal agents or HIV medications) may increase acalabrutinib concentrations, while strong CYP3A4 inducers (e.g., rifampicin) may decrease them. Blood thinners such as warfarin should also be used with caution in combination with acalabrutinib.
Treatment Context
Acalabrutinib can be used as a monotherapy or in combination with other agents, such as obinutuzumab (an anti-CD20 antibody). Treatment is generally continued until disease progression or unacceptable toxicity occurs. Regular blood count monitoring and medical supervision are essential throughout the course of treatment.
References
- European Medicines Agency (EMA): Calquence (Acalabrutinib) - Summary of Product Characteristics. Available at: https://www.ema.europa.eu
- Wang M. et al. - Acalabrutinib in relapsed or refractory mantle cell lymphoma. Journal of Hematology & Oncology, 2019.
- Sharman JP et al. - Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN). Lancet, 2020;395(10232):1278-1291.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categorySpondylarthrosis
Transverse fracture
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Acalabrutinib